A director at Argen X SE sold 426 shares at 547.910EUR and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showin...
argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025 August 19, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced it will host a webinar, titled “R&D Spotlight | Pioneering MuSK Biology with ARGX-119” on Tuesday, September 16, 2025, at 2:00pm ET. The webinar will be the first of a ‘mini’ series highlighting the argenx pipeline and research and development strategy. argenx management and scientific leadership will be joined by...
argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of Myasthenia Gravis Seles speaks out about her diagnosis with MG, a chronic autoimmune disease that causes muscle weakness, which can be severe and significantly impact daily life Partnership with Seles will highlight the ‘Go for Greater’ MG patient support initiative at the 2025 U.S. Open Tennis Championships August 12, 2025 6:45 AM EDT Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today ...
Following argenx' 2Q25 results with Vyvgart sales coming in at $ 949m, and beating CSS by 10%, we update our model, upping our Vyvgart sales estimates for FY25 to $ 3.98b (from $ 3.61b, Visible Alpha CSS: $ 3.97b). We factor in potential competition from IMAAVY (J&J), though we continue to see Vyvgart as the better product, and model approx. 12% q/q growth for 3Q25 and 4Q25. Additionally, we slightly tweak our CIDP numbers bringing us to higher peak sales ($ 4.22b vs. $ 3.76b). All in all, our t...
Ageas completes its 2024-2025 share buy-back programme Ageas completes its 2024-2025 share buy-back programme On Thursday 31 July 2025, Ageas completed the share buy-back programme it announced on 28 August 2024. Between 16 September 2024 and 31 July 2025, Ageas has bought back 3,910,230 shares corresponding to 1.97 % of the total shares outstanding and totalling EUR 200 million (rounded). Together with other treasury shares held by Ageas, the total number of shares now owned amounts to 4.13 % of shares issued. The overview of the completed share buy-back programme is available on our ....
Ageas achève son programme de rachat d’actions 2024-2025 Ageas achève son programme de rachat d’actions 2024-2025 Ageas a achevé, le jeudi 31 juillet 2025, le programme de rachat d’actions annoncé le 28 août 2024. Entre le 16 septembre 2024 et le 31 juillet 2025, Ageas a procédé au rachat de 3.910.230 actions, représentant 1,97% du total des actions en circulation et un montant total arrondi d’EUR 200 millions. En ce compris les autres actions déjà détenues par Ageas, le montant total des actions désormais détenues par Ageas s’élève à 4,13% des actions émises. Le récapitulatif relatif a...
Ageas voltooit inkoopprogramma eigen aandelen 2024-2025 Ageas voltooit inkoopprogramma eigen aandelen 2024-2025 Op donderdag 31 juli 2025 voltooide Ageas het aandelen-inkoopprogramma dat op 28 augustus 2024 werd aangekondigd. Tussen 16 september 2024 en 31 juli 2025 kocht Ageas 3.910.230 aandelen in. Dit komt overeen met 1,97% van het totale aantal uitstaande aandelen en met een totaalbedrag van afgerond EUR 200 miljoen. Samen met de eigen aandelen die Ageas al in bezit had, komt het totale aantal aandelen dat Ageas nu aanhoudt op 4.13%. Het volledige overzicht van het aandelen-inkooppro...
Alfen: Preview - muddling through? Belgian telcos: Competition Authority investigation on Proximus/Orange Belgium MoU. Brunel International: 2Q25 below, 3Q25 outlook cut, cost savings protect FY25 estimates. Euronext: Another record set of results. Fugro: Sharper V-shape? GBL: Weak NAV performance, as expected. KBC Ancora: Cooperative CERA increasing its stake to 51.24%, using excess cash. UCB: Renewed US threats to cut drug prices. Umicore: 1H25 and guide broadly in-line, new S...
1H25 adj. EBITDA increased by 10% to 433m and Umicore reiterated the (recently upgraded) FY25 adj EBITDA guidance of 790-840m (+7% y/y at midpoint), reflecting oa the progress with efficiency improvement measures and advantageous metal prices. Umicore is a combination of different tales, with the foundation businesses (Catalysis, Recycling, Specialty Materials) mainly run for their cash generation potential whilst Battery Materials remains a potential growth driver, although Umicore does not int...
argenx reported 1H25 results today, with Vyvgart sales showing a solid CSS beat. In this note you can find our main takeaways from the conference call. ARGX-119 phase 3 in CMS - argenx emphasized that they currently have 3 assets in phase 3 development with the advancement of ARGX-119 to phase 3 in Congenital Myasthenic Syndrome (CMS). ARGX-119 targets MuSK in the neuromuscular junction and is advanced in CMS, an ultra-rare disease. This allows for a small trial with dense monitoring of patients...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.